Abstract:Osteoclast serves as a pivotal mediator and communication hub within the subchondral bone, accelerating the onset and progression of osteoarthritis (OA). Aging‐related alterations (cellular senescence, inflammaging, mitochondrial dysfunction, abnormal histone modification, non‐coding RNAs, DNA methylation, dysregulated autophagy and molecular chaperones) significantly enhance osteoclast activities, thereby contributing to OA pathogenesis. Osteoarthritis (OA), a chronic degenerative joint disease, is highly prevalent among the aging population, and often leads to joint pain, disability, and a diminished quality of life. Although considerable research has been conducted, the precise molecular mechanisms propelling OA pathogenesis continue to be elusive, thereby impeding the development of effective therapeutics. Notably, recent studies have revealed subchondral bone lesions precede cartilage degeneration in the early stage of OA. This development is marked by escalated osteoclast‐mediated bone resorption, subsequent imbalances in bone metabolism, accelerated bone turnover, and a decrease in bone volume, thereby contributing significantly to the pathological changes. While the role of aging hallmarks in OA has been extensively elucidated from the perspective of chondrocytes, their connection with osteoclasts is not yet fully understood. There is compelling evidence to suggest that age‐related abnormalities such as epigenetic alterations, proteostasis network disruption, cellular senescence, and mitochondrial dysfunction, can stimulate osteoclast activity. This review intends to systematically discuss how aging hallmarks contribute to OA pathogenesis, placing particular emphasis on the age‐induced shifts in osteoclast activity. It also aims to stimulate future studies probing into the pathological mechanisms and therapeutic approaches targeting osteoclasts in OA during aging.

Development of novel osteoarthritis therapy by targeting AMPK-β-catenin-Runx2 signaling

AMPK: Implications in Osteoarthritis and Therapeutic Targets.

AMPK Activator Decelerates Osteoarthritis Development by Inhibition of Β-Catenin Signaling in Chondrocytes

Osteoarthritis: pathogenic signaling pathways and therapeutic targets

Signalling interaction between β‐catenin and other signalling molecules during osteoarthritis development

The involvement of signaling pathways in the pathogenesis of osteoarthritis: An update

Role of Wnt signaling pathway in joint development and cartilage degeneration

The Role of Mitochondrial Metabolism, AMPK-SIRT Mediated Pathway, LncRNA and MicroRNA in Osteoarthritis

Osthole Suppresses Knee Osteoarthritis Development by Enhancing Autophagy Activated via the AMPK/ULK1 Pathway

AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice

Subchondral osteoclasts and osteoarthritis: new insights and potential therapeutic avenues

Endothelial PDGF-BB/PDGFR-β signaling promotes osteoarthritis by enhancing angiogenesis-dependent abnormal subchondral bone formation

The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review

Promising targets for therapy of osteoarthritis: a review on the Wnt and TGF-β signalling pathways

The Wnt signaling cascade in the pathogenesis of osteoarthritis and related promising treatment strategies

Activation of Mtorc1 in Subchondral Bone Preosteoblasts Promotes Osteoarthritis by Stimulating Bone Sclerosis and Secretion of CXCL12

Osteoclasts and osteoarthritis: Novel intervention targets and therapeutic potentials during aging

Wnt and Rho GTPase Signaling in Osteoarthritis Development and Intervention: Implications for Diagnosis and Therapy

Emerging therapeutic targets for osteoarthritis

AFK-PD alleviated osteoarthritis progression by chondroprotective and anti-inflammatory activity

Cathelicidin-BF regulates the AMPK/SIRT1/NF-κB pathway to ameliorate murine osteoarthritis: In vitro and in vivo studie